stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) EBITDA
Grifols, S.A.'s EBITDA for fiscal 2025 was $1.9B, up 8.60% from $1.8B in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.9B. Over the past ten years it has ranged from $1.1B (fiscal 2021) to $1.9B (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 4 consecutive fiscal years. Grifols, S.A. ranks 14th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.9B | 8.60% |
| FY2024 | $1.8B | 31.28% |
| FY2023 | $1.3B | 5.07% |
| FY2022 | $1.3B | 13.18% |
| FY2021 | $1.1B | (24.95%) |
| FY2020 | $1.5B | (6.27%) |
| FY2019 | $1.6B | 11.21% |
| FY2018 | $1.4B | 4.82% |
| FY2017 | $1.4B | 9.08% |
| FY2016 | $1.3B | (1.96%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $451.2M | 8.59% |
| Mar 2026 | $415.5M | (6.88%) |
| Dec 2025 | $446.2M | (17.62%) |
| Sep 2025 | $541.6M | 2.84% |
| 27 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| NVO Novo Nordisk A/S compare | $27.2B |
| BMY Bristol Myers Squibb Company compare | $14.1B |
| GSK GSK PLC Sponsored ADR compare | $12.2B |
| SNY Sanofi compare | $11.1B |
| BIIB Biogen Inc. compare | $2.3B |
| GRFS Grifols, S.A. | $1.9B |
| OGN Organon & Co. compare | $1.4B |
| AMRN Amarin Corporation PLC compare | −$29.4M |
| NSRX Nasus Pharma Ltd. compare | — |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement